Literature DB >> 195975

Comparison of antibody-dependent cellular cytotoxicity and complement-dependent antibody lysis of herpes simplex virus-infected cells as methods of detecting antiviral antibodies in human sera.

T Subramanian, W E Rawls.   

Abstract

An antibody-dependent cellular cytotoxicity (ADCC) assay was used to detect antibodies to the herpes simplex viruses in humans sera. The assay utilized the release of 51Cr from BHK-21 cells infected with the viruses, hamster peritoneal exudate cells as effector cells, and antiviral antibodies in human sera. The technique was found to be far more sensitive than complement-dependent antibody lysis of infected cells and virus neutralization. The ADCC assay was useful in detecting antibodies in sera that had low titers or no antibodies detectable by other methods. In a sample of 100 sera from university students, 40 were positive by complement-dependent lysis whereas 73 were positive by ADCC. Of 400 sera from women with cervical cancer, 17 did not have detectable antibodies by microneutralization or complement-dependent lysis; however, all sera were positive by ADCC, suggesting that all of the women had been infected in the past with one or both types of herpes simplex virus.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 195975      PMCID: PMC274654          DOI: 10.1128/jcm.5.6.551-558.1977

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  28 in total

1.  Epidemiology of herpetic infections.

Authors:  T F M SCOTT
Journal:  Am J Ophthalmol       Date:  1957-04       Impact factor: 5.258

2.  Antibody-dependent cell-mediated cytotoxicity to target cells infected with type 1 and type 2 herpes simplex virus.

Authors:  S L Shore; C M Black; F M Melewicz; P A Wood; A J Nahmias
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

3.  Acute respiratory disease of university students with special reference to the etiologic role of Herpesvirus hominis.

Authors:  W P Glezen; G W Fernald; J A Lohr
Journal:  Am J Epidemiol       Date:  1975-02       Impact factor: 4.897

4.  Antibodies to Herpes simplex virus in Jewish women with cervical cancer and in healthy Jewish women of Israel.

Authors:  J Menczer; S Leventon-Kriss; M Modan; G Oelsner; C B Gerichter
Journal:  J Natl Cancer Inst       Date:  1975-07       Impact factor: 13.506

5.  Studies on herpes simplex virus. IV. The level of neutralizing antibodies in human sera.

Authors:  E JAWETZ; M F ALLENDE; V R COLEMAN
Journal:  J Immunol       Date:  1952-06       Impact factor: 5.422

6.  Antibodies to herpesvirus type 2 in carcinoma of the cervix uteri in Ibadan, Nigeria.

Authors:  B Adelusi; B O Osunkoya; A Fabiyi
Journal:  Am J Obstet Gynecol       Date:  1975-12-01       Impact factor: 8.661

7.  Quantitation of antibodies to Herpes simplex virus types 1 and 2 by complement-dependent antibody lysis of infected cells.

Authors:  H McClung; P Seth; W E Rawls
Journal:  Am J Epidemiol       Date:  1976-08       Impact factor: 4.897

8.  Long-term follow-up studies on herpes simplex antibodies in the course of cervical cancer. II. Antibodies to surface antigen of Herpes simplex virus infected cells.

Authors:  B Christenson; A Espmark
Journal:  Int J Cancer       Date:  1976-03-15       Impact factor: 7.396

9.  Herpesvirus antibodies and antigens in patients with cervical anaplasia and in controls.

Authors:  A S Pacsa; L Kummerländer; B Pejtsik; K Pali
Journal:  J Natl Cancer Inst       Date:  1975-10       Impact factor: 13.506

10.  Antibodies to herpesviruses in patients with cervical cancer and controls.

Authors:  N Muñoz; G de-Thé; N Aristizabal; C Yee; A Rabson; G Pearson
Journal:  IARC Sci Publ       Date:  1975
View more
  9 in total

1.  Herpes simplex virus glycoproteins: participation of individual herpes simplex virus type 1 glycoprotein antigens in immunocytolysis and their correlation with previously identified glycopolypeptides.

Authors:  B Norrild; S L Shore; A J Nahmias
Journal:  J Virol       Date:  1979-12       Impact factor: 5.103

2.  Participation of three major glycoprotein antigens of herpes simplex virus type 1 early in the infectious cycle as determined by antibody-dependent cell-mediated cytotoxicity.

Authors:  B Norrild; S L Shore; T L Cromeans; A J Nahmias
Journal:  Infect Immun       Date:  1980-04       Impact factor: 3.441

3.  Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2.

Authors:  N Balachandran; S Bacchetti; W E Rawls
Journal:  Infect Immun       Date:  1982-09       Impact factor: 3.441

4.  Neutralization capacity and antibody dependent cell-mediated cytotoxicity of separated IgG subclasses 1, 3 and 4 against herpes simplex virus.

Authors:  T Mathiesen; M A Persson; V A Sundqvist; B Wahren
Journal:  Clin Exp Immunol       Date:  1988-05       Impact factor: 4.330

5.  Effect of thymopentin on the mortality and immune response after an experimental herpes simplex infection in mice.

Authors:  R Cappel; F de Cuyper; K De Neef; W Höbel; K Bolla
Journal:  Surv Immunol Res       Date:  1985

6.  Cellular and humoral immune responses to herpes simplex virus during and after primary gingivostomatitis.

Authors:  A Møller-Larsen; S Haahr; F T Black
Journal:  Infect Immun       Date:  1978-11       Impact factor: 3.441

7.  Activity of rabbit monocytes, macrophages, and neutrophils in antibody-dependent cellular cytotoxicity of herpes simplex virus-infected corneal cells.

Authors:  J W Smith; A M Sheppard
Journal:  Infect Immun       Date:  1982-05       Impact factor: 3.441

8.  Human antibody-dependent cellular cytotoxicity and natural killer cytotoxicity to herpes simplex virus-infected autologous and allogeneic cells.

Authors:  S Kohl; C M Moore
Journal:  Immunology       Date:  1983-01       Impact factor: 7.397

9.  Failure of ADCC to predict HIV-associated disease progression or outcome in a haemophiliac cohort.

Authors:  A Dalgleish; A Sinclair; M Steel; D Beatson; C Ludlam; J Habeshaw
Journal:  Clin Exp Immunol       Date:  1990-07       Impact factor: 4.330

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.